A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Lung Cancer And Mesothelioma
  • Age: Between 18 years - 150 years
  • Gender: Male or Female
  • Other Inclusion Criteria:

    1. Patients must have been diagnosed with non-small cell lung cancer that progressed through at least one line of immune checkpoint inhibitor therapy (specifically, anti-PD-1/PD-L1 monotherapy, anti-CTLA-4 monotherapy, or combination therapy with anti-PD-1/PD-L1 and anti CTLA-4).

    2.  Patients may have been diagnosed with Melanoma and must have  progressed through one line of standard therapy.


You may not be eligible for this study if the following are true:

  • 1.  Symptomatic central nervous system (CNS) malignancy or metastasis

    2.  Known hypersensitivity to LY3022855, durvalumab, or tremelimumab, or to any combination or excipient.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.